BioSpace News Archive

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that new data from the Phase III study that evaluated linaclotide in children and adolescents aged 6-17 years with functional constipation were published in The Lancet Gastroenterology & Hepatology.

Element Biosciences, Inc., developer of pioneering technologies to empower science, has received over 160 commercial orders of its AVITI benchtop sequencer and expanded its installed base to 112 instruments, the company announced at the J.P. Morgan 42nd Annual Healthcare Conference.

Asieris Pharmaceuticals has announced its set-up of the Women’s Health Business Unit for commercialization.

Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, provided a corporate update, highlighted the Company’s key calendar year 2023 accomplishments and outlined its anticipated calendar year 2024 clinical development milestones.

Bausch Health Companies Inc. today announced that, as scheduled, oral arguments were heard today at the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc.

Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.

NeoGenomics, Inc., a leading oncology testing services company, and ConcertAI, LLC, a leading oncology real-world evidence data and AI technology company, today announced a broad collaboration to advance large-scale hematological research solution to investigate real-world clinical practice and outcomes in hematological malignancies.

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the achievement of two significant clinical milestones from its Hepatitis C Virus (HCV) and COVID-19 programs.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced preliminary, unaudited financial results for its fourth quarter and full year ended December 31, 2023.

Gossamer Bio, Inc. announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5, 2024, to two new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan.